Navigation Links
New study into bladder regeneration heralds organ replacement treatment
Date:11/19/2010

Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.

The research, led by Dr Arun Sharma and Earl Cheng from the Feinberg School of Medicine at Northwestern University and Children's Memorial Research Center, focused on bone marrow mesenchymal stem cells (MSCs) taken from the patient. Previously studies into the regenerative capacity of cells in bladders have focused on animal models, but these have translated poorly in clinical settings.

"Advances in the use of bone marrow stem cells taken from the patient opens up new opportunities for exploring organ replacement therapies, especially for bladder regeneration", said senior author Sharma. "Several findings from our study have demonstrated the plasticity of stem cells derived from bone marrow which make them ideal for this type of work."

The team discovered that bone marrow mesenchymal stem cells (MSCs) have phenotypic and physiological similarities with bladder smooth muscle cells (bSMCs) implying that MSCs can serve as an alternative cell source for potentially damaged bSMCs.

"For our research we developed a primate-based model, using the baboon bladder in conjunction with bone marrow MSCs to attempt partial bladder regeneration," said Sharma. "We found that the mesenchymal stem cells utilized throughout the study retained the ability to populate a surgically grafted area while remaining active 10 weeks after surgery."

The transplanted bone marrow cells also retained the ability to express key smooth muscle cell markers, attributes that are required for the continual expansion and contractile cycles of a functional bladder.

Currently information about the ce
'/>"/>

Contact: Peggy Murphy
pmjopnes@childrensmemorial.org
773-755-6341
Children's Memorial Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Businessman-philanthropist assists TGen-VARI study of rare cancer
2. Study shows importance of exercise for those at special risk for Alzheimers
3. Study eyes fluoxetine in recreational waters
4. Human health effects of e-waste focus of international research study
5. Hearing loss study reveals role of bone hardness in tissue function
6. Study rewrites the evolutionary history of C4 grasses
7. Clemson researcher will study plutonium underground for Energy Department
8. Study shows brass devices in plumbing systems can create serious lead-in-water problems
9. Study shows young, unsupervised children most at risk for dog bites
10. Chimerix Antiviral CMX001 Inhibits JC Virus Replication in Preclinical Study; Late-Breaker Presented at Antiviral Congress 2010
11. New ocean acidification study shows added danger to already struggling coral reefs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... - The meters-long, carnivorous "shrimp" from hell that once ruled the ... a real softy, it turns out. A new 3-D modeling of ... parts were not hard like teeth, but flexible, shows that the ... of trilobites and other such creatures of the early seas. ...
... Environmental Pollution " details successful experiments at the ... the abiotic (non-biological) transformation and absorption of four ... these estrogen hormones by more than 80 percent ... since it could point to inexpensive treatment technologies ...
... courses of antibiotics can leave normal gut bacteria harbouring ... treatment, say scientists writing in the latest issue of ... researchers believe that this reservoir increases the chances of ... survival and suggesting that the long-term effects of antibiotic ...
Cached Biology News:Earth's first great predator wasn't 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 2UC research: Rabbit's food brings luck in decreasing estrogen levels in wastewater 3Antibiotics have long-term impacts on gut flora 2
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... Ltd., a,privately-held drug development company with its headquarters ... new Phase IIa clinical testing of,ProtoCure(TM) emulsion cream, ... vehicle-controlled study is designed to,evaluate the tolerability, pharmacokinetics, ... of 18 subjects with mild to moderate plaque ...
... through non core divestitures - , - Caliper signs ... , - Non-cash restructuring and goodwill impairment charge ... Caliper Life Sciences, Inc. (Nasdaq: CALP ), today ... 2008. Fourth quarter revenues were $36.7 million, a decline ...
... Simcere Pharmaceutical Group,("Simcere" or the "Company,) (NYSE: ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product Endu ... and fiscal year ended December 31, 2008. , , ... revenue increased to RMB 466.9 million (US$68.4 million) for ...
Cached Biology Technology:BioCis Pharma Starts Phase IIa Trial in Psoriasis 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 2Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 3Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 4Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 5Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 6Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 7Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 8Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 9Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 10Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 11Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 12Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 13Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results 14Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13
Lingo-1 (K-13)...
HIF-1 beta (ARNT1) Purified Anti-Mouse, Anti-Rat, Anti-Human clone 29, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: